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strategy to restore perfusion of ischemic tissues in patients
with peripheral arterial disease. The 14q32 microRNA cluster
is highly involved in neovascularization. The Mef2a transcrip-
tion factor has been shown to induce transcription of the
microRNAs within this cluster. We inhibited expression of
Mef2a using gene-silencing oligonucleotides (GSOs) in an
in vivo hind limb ischemia model. Treatment with GSO-
Mef2a clearly improved blood flow recovery within 3 days
(44% recovery versus 25% recovery in control) and persisted
until 14 days after ischemia induction (80% recovery versus
60% recovery in control). Animals treated with GSO-Mef2a
showed increased arteriogenesis and angiogenesis in the rele-
vant muscle tissues. Inhibition of Mef2a decreased expression
of 14q32 microRNAs miR-329 (p = 0.026) and miR-494 (trend,
p = 0.06), but not of other 14q32 microRNAs, nor of 14q32
microRNA precursors. Because Mef2a did not influence
14q32 microRNA transcription, we hypothesized it functions
as an RNA-binding protein that influences processing of
14q32 microRNA miR-329 and miR-494. Mef2A immunopre-
cipitation followed by RNA isolation and rt/qPCR confirmed
direct binding of MEF2A to pri-miR-494, supporting this
hypothesis. Our study demonstrates a novel function for
Mef2a in post-ischemic neovascularization via post-transcrip-
tional regulation of 14q32 microRNAs miR-329 and miR-494.Received 2 February 2017; accepted 3 March 2017;
http://dx.doi.org/10.1016/j.omtn.2017.03.003.
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Patients with peripheral arterial disease (PAD) suffer from reduced
blood supply toward the extremities caused by the build-up of
obstructive atherosclerotic plaques in the arterial wall. Restoration
of blood flow in these patients is imperative for the prevention of crit-
ical limb ischemia and limb loss. This can be accomplished by stim-
ulating post-ischemic neovascularization, i.e., arteriogenesis and
angiogenesis. Arteriogenesis, the outward remodeling of pre-existent
collateral arterioles, is initiated upon increases in shear stress through
the arterioles.1 Angiogenesis is driven by ischemia and leads to
sprouting of new capillaries from existing blood vessels into the
ischemic tissue.2 Both arteriogenesis and angiogenesis are multifacto-
rial processes that involve, for example, the activation of endothelialMolecul
This is an open access article under the CC BY-Ncells (ECs), proliferation of vascular cell types (especially smooth
muscle cells [SMCs]), and recruitment of immune cells.
MicroRNAs are short, non-coding RNA molecules that regulate the
expression of their target genes at the post-transcriptional level.3
Each microRNA has multiple target genes, and microRNA binding
to a target messenger RNA downregulates the expression of that
gene. The ability of microRNAs to target numerous genes makes
them attractive targets for the regulation of multifactorial physiolog-
ical processes. In the past decade, microRNAs have emerged as key
regulators in the development and progression of cardiovascular
disease.4–9 Recently, we have shown the involvement of multiple
microRNAs from a single microRNA cluster located on human
chromosome 14q32 in post-ischemic neovascularization.10 The
14q32 locus contains the largest known mammalian microRNA
gene cluster and contains 54 microRNAs in humans (12F1 locus
in mice containing 61 microRNAs).11 In our previous study,
we showed that inhibition of microRNAs miR-329, miR-487b,
miR-494, and miR-495 from the 14q32 microRNA cluster led to
improved blood flow recovery after induction of hind limb ischemia
in mice.10 Arteriogenesis and angiogenesis were both increased in
the adductor and soleus muscles of these mice, respectively. Myo-
cyte enhancer factor 2a (Mef2a) was confirmed as a target gene of
miR-329, and Mef2a expression was upregulated in the ligated
hind limb after miR-329 inhibition. Interestingly, MEF2A itself
was reported to target miR-329 and the other 14q32 microRNAs.12
Several studies reported transcriptional regulation of the 14q32
microRNA cluster by the MEF2 family of transcription factors
and, in particular, by MEF2A.12–14
The MEF2 family of transcription factors consists of four mem-
bers, namely, MEF2A, MEF2B, MEF2C, and MEF2D. Althoughar Therapy: Nucleic Acids Vol. 7 June 2017 ª 2017 The Author(s). 61
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Figure 1. Inhibition of Mef2a by GSOs
(A) Four different GSOs were developed and tested for their capacity to inhibit Mef2a expression in vitro. GSOs were designed to target different exons on the murine Mef2a
mRNA sequence. (B) Inhibition of Mef2a in primary murine vascular smooth muscle cells for 48 hr by GSOs (10 ng/mL). Mean expression levels, from at least three inde-
pendent experiments, relative to HPRT and as a percentage of GSO-control are shown here (±SEM). **p < 0.01; ***p < 0.001.
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tiation, MEF2 family members are also expressed in ECs and
vascular SMCs.15,16 MEF2A and MEF2C are the predominant iso-
forms expressed in vascular cells. In ECs, MEF2 proteins have been
shown to control vascular integrity by promoting EC survival,
whereas in SMCs, MEF2 proteins are expressed in cells with an
activated phenotype and control differentiation of SMCs.17,18
Moreover, inhibition of MEF2A induced phenotypic switching of
vascular SMCs, leading to proliferation and migration of these
cells.19
The aim of this study was to evaluate the effect of Mef2a inhibition on
post-ischemic blood flow recovery. We hypothesized that Mef2a
could act as a novel switch in neovascularization via regulation of
14q32 microRNAs. We show here that inhibition of Mef2a, via sub-
sequent inhibition of 14q32 microRNAs miR-329 and miR-494, but
not other 14q32 microRNAs, indeed improves post-ischemic blood
flow recovery in vivo.
RESULTS
Gene Silencing Oligonucleotide Mediated Inhibition of Mef2a
Expression
We tested several gene silencing oligonucleotides (GSOs) in vitro for
their capacity to inhibit Mef2a mRNA expression in murine primary
SMCs (GSO-1, GSO-2, GSO-3, and GSO-4; Figure 1A). Expression of
Mef2a was significantly inhibited by GSO-2 (35% expression of con-
trol, p = 0.0005) and GSO-3 (30% expression of control, p = 0.0094),
but not by treatment with GSO-1 or GSO-4 (Figure 1B). For in vivo
experiments, we selected GSO-3 for inhibition of Mef2a (GSO-Mef2a
from here on), which gave the strongest downregulation of Mef2a
expression.62 Molecular Therapy: Nucleic Acids Vol. 7 June 2017In Vivo Inhibition of Mef2a Using GSOs
Immunohistochemical staining of murine adductor muscle tissue
demonstrated that MEF2A is expressed in this tissue, particularly in
the nuclei of cells (Figure 2A). Expression of Mef2a was measured
in the adductor and gastrocnemius muscles of animals, 14 days after
induction of ischemia and 4 days after the final GSO injection.
Expression of Mef2a was downregulated in both adductor and
gastrocnemius muscle tissue of GSO-Mef2a-treated mice compared
to control-treated animals (Figures 2B and 2C, respectively).
Although inhibition of Mef2a was less strong than in vitro cell
cultures, inhibition was highly significant (72% expression of control,
p = 0.00052 in the adductor, and 78% expression of control,
p < 0.0001 in the gastrocnemius muscle). GSO-Mef2a treatment
furthermore reduced MEF2A protein levels in the adductor muscle
by 30% (Figure 2D).
Improved Blood Flow Recovery upon Mef2a Inhibition
The effect ofMef2a inhibition on blood flow recovery was evaluated at
different time points after ligation of the femoral artery (pre-opera-
tive, post-operative, day 3, day 7, day 10, and day 14 after ischemia
induction; Figure 3). Within 3 days after hind limb ischemia, animals
injected with GSOs against Mef2a already showed improved blood
flow recovery (44% recovery in GSO-Mef2a animals versus 25% re-
covery in GSO-control animals; Figure 3). This increase in perfusion
persisted over time. At time of sacrifice, GSO-Mef2a-treated animals
showed 80% recovery in blood flow compared to 60% recovery of
perfusion in GSO-control-treated animals.
In Vivo Inhibition of Mef2a Increases Arteriogenesis
Alpha smooth muscle actin (a-SMA+) staining was used to visualize
collateral vessels in the adductor muscle. Significant increases in
Figure 2. In Vivo Inhibition of Mef2a by GSO-Mef2a
(A) Immunohistochemical staining of MEF2A in the
adductor muscle of GSO-Mef2a- and GSO-control-treated
mice. (B) mRNA expression of Mef2a in the adductor
muscle of C57BL/6 mice treated with GSO-Mef2a or GSO-
control, 14 days after double ligation of the left femoral ar-
tery. Per group, adductor muscle tissue of ten animals was
used. (C) Expression of Mef2a in the gastrocnemius muscle
of C57BL/6 mice treated with GSO-Mef2a or GSO-control,
14 days after ischemia induction. Per group, gastrocnemius
muscle tissue of ten animals was used. Mean expression
levels relative to HPRT are shown here (±SEM). (D) MEF2A
and actin protein expression and quantification in adductor
muscle lysates of GSO-Mef2a- (M) and GSO-control
(C)-treated mice (n = 2 animals per group). Mean expres-
sion as a percentage of control is shown here (±SEM).
***p < 0.001; ****p < 0.0001.
www.moleculartherapy.orgarteriole diameters were observed between the left and right
adductor muscles for GSO-Mef2a-treated mice compared to GSO-
control-treated mice (increase in arteriole diameter in left over right
adductor [LA/RA ratio] was 2.057 compared to the LA/RA ratio of
1.16 in controls, p = 0.0060; Figure 4A). Both total a-SMA+ area per
section (LA GSO-Mef2a 846 ± 99 mm2 versus RA GSO-Mef2a 404 ±
37 mm2, p = 0.00043, and LA GSO-control 654 ± 68 mm2 versus RA
GSO-control 480 ± 27 mm2, p = 0.05) as well as mean lumen area per
a-SMA+ collateral (LA GSO-Mef2a 342 ± 25 mm2 versus RA GSO-
Mef2a 170 ± 9 mm2, p = 0.0002, and LA GSO-control 237 ± 47 mm2
versus RA GSO-control 217 ± 18 mm2, p = 0.54) were increased in
the left adductor muscles of GSO-Mef2a-treated animals compared
to the right adductor muscles, which was not the case for GSO-con-
trol-treated animals (Figures 4B and 4C, respectively). Moreover,
a-SMA+ area per collateral was increased in the left adductor of
GSO-Mef2a-treated animals compared to controls (GSO-Mef2a
342 ± 25 mm2 versus GSO-control 237 ± 47 mm2, p = 0.03; Figure 4C
and representative images in Figure 4D). The number of a-SMA+
vessels between the left and right paw were similar in the GSO-
Mef2a group (LA/RA ratio 1.04), whereas GSO-control-treated an-
imals had more a-SMA+ vessels in the left compared to the rightMolecpaw (LA/RA ratio 1.27; Figure 4E). Arteriogen-
esis is the enlargement of pre-existing arterioles
to form collateral arteries. Therefore, not the in-
crease in number of collateral arteries, but rather
the increase in arteriole diameters demonstrate
increased arteriogenesis in GSO-Mef2a-treated
mice. Furthermore, because an inflammatory
environment facilitates extracellular matrix re-
arrangement and outward remodeling of collat-
eral arterioles, we also looked at the number of
inflammatory cells surrounding the collaterals.
There was a trend toward an increase in the
number of perivascular CD45+ leukocytes
around the remodeling collaterals of GSO-
Mef2a-treated animals compared to controls(64% increase compared to GSO-control animals, p = 0.09;
Figure 4F).
In Vivo Angiogenesis upon Mef2a Inhibition
Capillary formation was evaluated in the left (ischemic) and right
(normoxic) soleus muscles of GSO-treated mice, 14 days after in-
duction of ischemia. Muscle tissues were stained with anti-CD31
to visualize capillaries. Inhibition of Mef2a increased capillary
formation in the soleus muscles of these mice (1.4-fold, p =
0.04) compared to the soleus muscles of GSO-control-treated
mice (Figure 5). We also investigated the effect of Mef2a inhibi-
tion on ex vivo angiogenesis using aortic explants. GSO-medi-
ated inhibition of Mef2a led to a mild increase in the number
of sprouts from aortic explants compared to GSO-control
(Figure S1).
Mef2a Targets miR-329 and miR-494 of the 14q32 MicroRNA
Cluster
We determined expression of 14q32microRNAsmiR-329, miR-487b,
miR-494, miR-495, and miR-410 in the adductor muscles of GSO-
Mef2a- and GSO-control-treated mice. Inhibition of Mef2a led toular Therapy: Nucleic Acids Vol. 7 June 2017 63
Figure 3. Blood Flow Recovery after In Vivo Mef2a
Inhibition
(A) LDPI from paws of mice subjected to unilateral hind
limb ischemia showing blood flow recovery in these ani-
mals over time. (B) Quantification of LDPI measurements
over time in mice (11 per group) treated with GSO-Mef2a
or GSO-control (1 mg per mouse injected i.p. at different
time points as described in Materials and Methods). Data
are calculated as the ratio of the left (ischemic) over the
right (non-ischemic) paw and presented as mean ± SEM.
p values are shown for each time point.
Molecular Therapy: Nucleic Acidssignificant downregulation of 14q32 microRNA miR-329 (Figure 6A;
p = 0.0026) and a borderline significant downregulation of miR-494
(Figure 6B; p = 0.06). However, expression of 14q32 microRNAs
miR-487b, miR-410, and miR-495 was not inhibited in animals
treated with GSO-Mef2a (Figures 6C–6E). MicroRNAs are tran-
scribed as primary microRNAs (pri-miRs) before being processed
into pre-microRNAs (pre-miRs) and subsequently into mature
microRNAs. To determine whether Mef2a does influence transcrip-
tion of multiple 14q32 microRNAs, we also measured expression of
the pri-miR transcripts and the intermediate pre-miRs in adductor
muscle tissue of GSO-treated animals. No differences were observed
in pri-miR and pre-miR levels of any of the microRNAs between
GSO-Mef2a- and GSO-control-treated animals, indicating that the
regulation of mature miR-329 and miR-494 levels was indirect
(Figure 7A).
Mef2a Binds to the Pri-miR Transcript of 14q32 MicroRNA miR-
494, but Not to miR-487b
To investigate whether Mef2a could regulate post-transcriptional
processing of 14q32 microRNAs, we performed RNA-binding pro-
tein immunoprecipitation (RIP) assays. RIP experiments on 3T3
cell lysates performed with anti-MEF2A antibodies demonstrated
specific binding of MEF2A to the pri-miR-494 transcript, but not
to the pri-miR-487b transcript (Figure 7B). Expression of pri-
miR-329 was too low to confirm or exclude MEF2A binding in
these cells.
DISCUSSION
We demonstrate here that the Mef2a transcription factor plays a role
in post-ischemic neovascularization. Inhibition of MEF2A improved
blood flow recovery in animals after unilateral ligation of the femoral
artery. Previous reports have demonstrated the role of Mef2a in other
forms of vascular remodeling as well. One study showed that the64 Molecular Therapy: Nucleic Acids Vol. 7 June 2017expression of MEF2 members Mef2a, Mef2b,
and Mef2d was increased in the neointima of
rat carotid arteries after balloon injury.18 In
another study, overexpression of a dominant-
negative mutant form of Mef2a reduced neoin-
tima formation, inhibited macrophage infiltra-
tion, and decreased MCP1 expression upon
wire injury in rats.20 However, to our knowl-edge, a role of Mef2a in post-ischemic neovascularization is a
completely novel finding.
We hypothesized that inhibition of Mef2a expression would improve
post-ischemic neovascularization via subsequent downregulation of
14q32 microRNAs because Mef2a was reported to control 14q32
microRNA expression and because we have previously shown that
14q32 microRNAs have anti-angiogenic and anti-arteriogenic func-
tions.10,12 Inhibition of Mef2a in our study revealed decreased expres-
sion of 14q32 microRNA miR-329 and a trend toward decreased
expression of miR-494, but not of several other 14q32 microRNAs
studied here. Indeed, animals treated with GSO-Mef2a showed
80% recovery of blood flow, 14 days after ischemia induction. How-
ever, this effect was not greater than inhibition of single 14q32
microRNAs miR-329 andmiR-494 because inhibition of these micro-
RNAs led to (nearly) complete restoration of blood flow within 7 and
10 days, respectively.
In addition to the mature miR levels, we also determined expression
levels of pri-miR transcripts and pre-miR intermediates of several
14q32 microRNAs. Pri-miR levels directly indicate the level of tran-
scription of the 14q32 microRNA genes, which were expected to be
influenced by the transcription factor Mef2a. Pre-miRs are an inter-
mediate form of the microRNA transcript, and changes in expression
of the pri-miR to the pre-miR or from pre-miR to the mature
microRNA indicate changes in post-transcriptional processing
of the microRNA. Pri-miR and pre-miR levels for miR-329, miR-
487b, miR-494, and miR-495 showed no difference in expression
levels between the GSO-treated groups. These data indicate that there
is no direct transcriptional regulation by MEF2a of the 14q32
microRNAs studied here in this model and that the effects on mature
miR-329 andmiR-494 levels were achieved through other mechanism
than transcription. Using RIP experiments, we demonstrated specific
Figure 4. In Vivo Arteriogenesis after Mef2a Inhibition
Immunofluorescence staining of paraffin-embedded adductor muscle group of C57BL/6 mice treated with either GSO-control (n = 11 animals) or GSO-Mef2a (n = 10
animals), 14 days after ischemia induction, using anti-aSMA (turquoise) antibodies. (A) Quantification of the increase in diameter of a-SMA+ arterioles between the left and the
right adductor muscles of mice. (B and C) Total a-SMA+ area per section (B) as well as mean lumen area per a-SMA+ collateral (C) are shown. (D) Representative images of
a-SMA staining in unligated and ligated adductor muscle tissues of mice treated with GSO-Mef2a or GSO-control. (E) Number of total collateral arterioles in left (ligated) over
right (unligated) adductor muscles of mice. (F) Quantification of the number of CD45+ cells around remodeling collateral arterioles in the adductor muscle of GSO-control- or
GSO-Mef2a-treated mice, 14 days after induction of ischemia. From each muscle, eight representative images were used for quantification. Data are presented as mean ±
SEM. *p < 0.05; *p < 0.001; ***p < 0.0005.
www.moleculartherapy.orgbinding of MEF2A to the pri-miR-494 transcript, but not to pri-miR-
487b, a microRNA that was not regulated by Mef2a inhibition in our
study. Because pri-miR-329 levels were too low in 3T3 cells, we could
not confirm or exclude MEF2A binding. Nonetheless, we show here
for the first time that MEF2Amay not only function as a transcription
factor, but potentially also as an RNA-binding protein. Future exper-
iments will have to determine whether MEF2A can regulate post-
transcriptional processing of other 14q32 microRNAs as well as
non-14q32 microRNAs. For example, a recent study demonstrated
that MEF2A, via miR-143, regulates proliferation, migration, and
H2O2-induced senescence of vascular SMCs.
21 This work by Zhao
et al. indeed shows that MEF2A can also regulate expression of
microRNAs outside the 14q32 gene cluster.
In the study by Snyder et al.,12 microarray analysis of injured muscle
tissue from Mef2a knockout mice revealed downregulation of
multiple microRNAs located on mouse chromosome 12F1 (14q32in humans), indicating regulation of the 12F1/14q32 region by
Mef2a, at least in response to injury. To evaluate the role of Mef2a
in skeletal muscle regeneration, the authors induced muscle injury
in mice.12 In our study, wemade use of the hind limb ischemia model
to investigate the role of Mef2a in post-ischemic neovascularization,
in which no direct damage to the muscle itself was introduced.
Furthermore, Snyder et al. determined the expression of 14q32
microRNAs in (injured) muscle tissue of Mef2a knockout mice,
whereas we measured expression of 14q32 microRNAs in C57BL/6
muscle tissue, wherein Mef2a expression was reduced by 25%
only using GSOs.12 These differences in the chosen models may
explain the observed discrepancies in the regulation of 14q32
microRNAs by Mef2a.
Following the improved blood flow recovery in GSO-Mef2a-treated
mice, we observed increased arteriogenesis in the adductor muscle
of these mice. Phenotypic switching of SMCs, from a contractile toMolecular Therapy: Nucleic Acids Vol. 7 June 2017 65
Figure 5. In Vivo Angiogenesis after Mef2a Inhibition
(A) Representative images of CD31 staining in the right (non-ischemic) and left
(ischemic) soleus muscles of C57BL/6 mice treated with GSO-Mef2a (n = 10 ani-
mals) or GSO-control (n = 11 animals). (B) Quantification of the capillary density in
the soleus muscle, defined as the increase in CD31+ area between the left and right
soleus muscles, shown as a percentage relative to the increase in mice treated with
GSO-control. From each soleus muscle, six representative photographs were used
for quantification. Data are presented as mean ± SEM. *p < 0.05.
Molecular Therapy: Nucleic Acidsa proliferative state, is an important process in arteriogenesis and
other forms of vascular remodeling.22 Our results would imply that
inhibition of Mef2a stimulates proliferation of SMCs because GSO-
Mef2a-treated animals showed increased aSMA+ collateral areas
compared to GSO-control-treated mice. These findings are in line
with the study by Zhao et al.,19 who reported increased proliferation
and migration of human SMCs and downregulation of SMC markers
upon MEF2A siRNA treatment. Firulli et al.18 reported that the high
levels of MEF2A expression in the neointima of rats upon balloon
injury correlated with an activated SMC phenotype rather than a
mere differentiated phenotype. In addition, we observed increased
angiogenesis in the ischemic soleus muscle of GSO-Mef2a-treated an-
imals. Collectively, our data suggest that Mef2a plays a role in SMC
differentiation and proliferation as well as EC proliferation.
In conclusion, our study demonstrates a novel function for MEF2A
in post-ischemic neovascularization and provides a link among
MEF2A, 14q32 microRNAs miR-329 and miR-494, and arteriogen-
esis and angiogenesis. Furthermore, we show for the first time that
Mef2a is not only a DNA-binding protein that regulates transcrip-
tion, but also an RNA-binding protein that may regulate post-tran-66 Molecular Therapy: Nucleic Acids Vol. 7 June 2017scriptional processing of microRNAs. MEF2A acts as a novel switch
in vascular remodeling and neovascularization, and MEF2A inhibi-
tion increases blood flow recovery and tissue perfusion. However,
because the effects of direct 14q32 microRNA inhibition on post-
ischemic neovascularization are much larger, MEF2A inhibition
is unlikely to be a promising therapeutic strategy to increase neo-




GSOs were designed with reverse complementarity to the murine
Mef2a target mRNA sequence and synthesized at Idera Pharmaceu-
ticals.23 As negative control, a scrambled sequence was used, de-
signed not to target any known murine mRNA. GSOs were made
up of two single-stranded DNA strands, which were 20O-methyl-
ated. The two DNA strands were linked together at their 50 ends
by a phosphothioate linker in order to prevent Toll-like-receptor-
mediated immune activation. Sequences of Mef2a GSOs are given
in Figure 1.
Hind Limb Ischemia Model
This study was performed in accordance with Dutch government
guidelines and the Directive 2010/63/EU of the European Parliament.
All experiments were approved by the committee on animal welfare of
the Leiden University Medical Center (approval reference number
12029). C57BL/6male mice, aged 8 to 12 weeks (Harlan), were housed
in groups of four or five mice, with free access to water and regular
chow. For Mef2a-inhibition experiments, mice were given intraperi-
toneal (i.p.) injections of 1 mg (40 mg/kg) GSO in PBS or PBS alone
at 10, 7, and 4 days directly before surgery and at 3, 7, and 10 days after
surgery. Mice were anesthetized by i.p. injection of midazolam
(8 mg/kg, Roche Diagnostics), medetomidine (0.4 mg/kg, Orion),
and fentanyl (0.08 mg/kg, Janssen Pharmaceuticals). Unilateral hind
limb ischemia was induced by electrocoagulation of the left femoral
artery proximal to the superficial epigastric artery and proximal to
the bifurcation of the popliteal and saphenous artery (double ligation
model).24 After surgery, anesthesia was antagonized with flumazenil
(0.7 mg/kg, Fresenius Kabi), atipamezole (3.3 mg/kg, Orion), and
buprenorphine (0.2 mg/kg, MSD Animal Health).
Laser Doppler Perfusion Measurements
Blood flow recovery to the ligated hind limb was measured over time
using laser Doppler perfusion imaging (LDPI) (Moor Instruments)
before and directly after surgery and at 3, 7, 10, and 14 days after
surgery. For LDPI measurements, mice were anesthetized by i.p. in-
jection of midazolam (8 mg/kg, Roche Diagnostics) and medetomi-
dine (0.4 mg/kg, Orion). Before each measurement, mice were placed
in a double-glazed pot and perfused with water at 37C for 5 min. Af-
ter LDPI, anesthesia was antagonized by subcutaneous injection of
flumazenil (0.7 mg/kg, Fresenius Kabi) and atipamezole (3.3 mg/kg,
Orion). LDPI measurements in the ligated paw were normalized
to measurements of the unligated paw as the internal control.
After the last LDPI measurement at day 14, analgesic fentanyl
Figure 6. Regulation of 14q32 MicroRNA Expression In Vivo
(A–E) Expression of 14q32 microRNAs miR-329 (A), miR-494 (B), miR-487b (C), miR-410 (D), and miR-495 (E) in adductor muscle tissue of GSO-Mef2a- or GSO-control-
treated animals at 14 days after hind limb ischemia. Per group, adductor muscle tissue of four mice was used. Mean expression levels are shown here relative to expression of
let-7c (±SEM). *p < 0.05.
www.moleculartherapy.org(0.08 mg/kg, Janssen Pharmaceuticals) was administered subcutane-
ously and mice were sacrificed via cervical dislocation. The adductor,
gastrocnemius, and soleus muscles were harvested and either snap-
frozen or fixed in 4% paraformaldehyde (PFA).
Cell Culture
Primary Murine SMCs
Primary murine SMCs were isolated from mouse aortae of C57BL/6
mice. Aortae were cut into small pieces and embedded on gelatin-
coated six-well plates. Culture medium was added to the wells
with aortic fragments (DMEM [Invitrogen, GIBCO], 10% heat inac-
tivated fetal bovine serum [PAA], and 1% penicillin/streptomycin).
Outgrowth of SMCs occurred within 1 week, after which cells were
passed using Trypsin-EDTA (Sigma) and transferred to fresh six-
well plates. SMCs were characterized by positive a-SMA staining as
described previously.10 Cells were cultured at 37C in a humidified
5% CO2 environment.
3T3 Cells
3T3 cells were cultured at 37C in a humidified 5% CO2 environment.
Culture medium consisted of DMEM GlutaMAX (GIBCO) supple-
mented with 10% heat inactivated fetal bovine serum (PAA) and
1% penicillin/streptomycin (PAA). Culture medium was refreshed
every 2 to 3 days. Cells were passed using trypsin-EDTA (Sigma) at
90% confluency.
In Vitro GSO-Mediated Inhibition of Mef2a Expression
For GSO experiments, murine SMCs were plated at 50,000 cells per
well of a 12-well plate. After 24 hr, GSOs against Mef2a were addedto the culture media at a concentration of 10 ng/mL for 48 hr. After
48 hr, cells were washed with PBS and TRIzol (Invitrogen) was added
to the cells for RNA isolation.
qRT-PCR
mRNA qRT-PCR
Adductor and gastrocnemius muscles from 14 days after surgery were
homogenized by grounding with a pestle andmortar in liquid nitrogen.
Total RNA was isolated using a standard TRIzol-chloroform extrac-
tion protocol. RNA concentration and purity were determined by
nanodrop (Nanodrop Technologies). RNA was reverse transcribed us-
ing high-capacity RNA to cDNA RT kits (Life Technologies). Relative
quantitative mRNAPCRwas performed on reverse-transcribed cDNA
usingMef2a Taqman gene expression assays. For quantification of pri-
miR and pre-miR levels of microRNAs, SYBR green dye (QIAGEN)
was used, and primers were designed using Primer3. Sequences of
primers are listed in Table S1. qPCRs were run on a 7900HT Fast
Real-Time PCR system (Applied Biosystems), and amplification effi-
ciencies were checked by standard curves. Data were normalized using
a stably expressed endogenous control (HPRT for Mef2a quantifica-
tion and snRNA-U6 for pri-miR and pre-miR quantification).
MicroRNA qRT-PCR
microRNA quantification was performed using Taqman microRNA
assays (Applied Biosystems) according to the manufacturer’s proto-
col. Relative qPCR was performed on the Viia7 system (Applied Bio-
systems), and amplification efficiencies were checked by standard
curves. Data were normalized using a stably expressed endogenous
control (mmu-let-7c), as previously described.25Molecular Therapy: Nucleic Acids Vol. 7 June 2017 67
Figure 7. Regulation of 14q32 Pri-miR and Pre-miR
Expression In Vivo
(A) Expression of pri-miR and pre-miR transcripts of
14q32 microRNAs miR-329, miR-487b, miR-494, and
miR-495 in adductor muscle tissue of GSO-Mef2a- or
GSO-control-treated animals at 14 days after hind limb
ischemia. Per group, adductor muscle tissue of 11 mice
was used. Mean expression levels are shown here relative
to expression of snRNA-U6 (±SEM). (B) RNA-binding
protein immunoprecipitation with either MEF2A anti-
bodies or negative control rabbit IgG followed by
qRT-PCR on pri-miR transcripts of 14q32 microRNAs
miR-494 and miR-487b. Data are normalized against
10% input.
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CD31
6-mm-thick fresh-frozen cross-sections of soleus muscle were fixed in
ice-cold acetone and stained with anti-CD31 (BD PharMingen).
Sections were counterstained with hematoxylin. Quantification of
the CD31-positive area was performed on sections photographed
randomly (six representative images per muscle per mouse, ten
animals per group) using image analysis (ImageJ 1.48v, NHI), as
described previously.26
a-SMA, CD31, and CD45 Triple Staining
5-mm-thick paraffin-embedded cross-sections of adductor muscle
were re-hydrated, and antigen retrieval was performed using
citrate buffer. SMCs were stained using primary antibodies against
a-SMA (DAKO), ECs were stained with CD31 antibodies (BD
PharMingen), and leukocytes were stained using CD45 antibodies
(Abcam). Alexa Fluor 647, Alexa Fluor 488, and Alexa Fluor 594
antibodies (Life Technologies and Invitrogen [Alexa Fluor 594])
were used to visualize SMCs, ECs, and leukocytes, respectively.
Finally, sections were mounted in Fluoroshield with DAPI
(Sigma-Aldrich). The Pannoramic MIDI digital slide scanner
(3DHistech) was used to create high-resolution images of the
adductor muscles. Snapshots were taken using the Pannoramic
viewer software (3DHistech) with 20 magnification. The amount
and size of a-SMA positive collaterals was measured using ImageJ
(ImageJ 1.48v, NHI).
MEF2A
5-mm-thick paraffin-embedded cross-sections of adductor muscle
were re-hydrated, and endogenous peroxidase activity was blocked.
Antigen retrieval was performed with Tris-EDTA (pH 9.0) at
100C for 10 min. Adductor muscles were stained with anti-
MEF2A antibodies (Abcam, ab86755) to visualize MEF2A expression
and counterstained with hematoxylin.
Western Blot Analysis
Immunoblotting was performed to quantify MEF2A expression
in vivo. Homogenized adductor muscle tissue of GSO-control-
(n = 2) and GSO-Mef2a-treated animals (n = 2) were lysed on ice
for 30 min with lysis buffer. Lysates were briefly centrifuged to re-
move debris. Equal amounts of protein (20 mg per sample) were
loaded onto a PAGEminigel (Mini-PROTEAN TGX precast gel, Bio-
rad) and run at 70 V for 10 min and subsequently at 120 V for 90 min.
Fractionated tissue extracts were transferred to a nitrocellulose mem-
brane using a transfer apparatus according to the manufacturer’s
protocol (Bio-Rad). Incubation with primary rabbit anti-MEF2A
antibody (Abcam, ab86755 1:100) was followed by incubation with
horseradish peroxidase (HRP)-conjugated secondary antibody goat
anti-rabbit immunoglobulin G (IgG) (CST7074, Cell Signaling Tech-
nology). Signals were visualized using the SuperSignal ELISA Pico
chemiluminescent substrate (ThermoScientific). Blots were stripped
for 15 min using Restore Stripping Buffer (ThermoScientific) and
incubated with anti-actin (C-11) (SC1615, Santa-Cruz) for normali-
zation. The proportional expression of MEF2A per lane was normal-ized against the proportional expression of actin per lane (Biorad
Image Lab Software 5.2.1).
Aortic Ring Assay
Mouse aortic ring assays were performed as described previously.27 In
brief, the thoracic aorta was removed from 8- to 10-week-old mice
and transferred to a 15-mL tube containing Opti-MEM (GIBCO).
Surrounding fat and branching vessels were carefully removed, and
aortas were flushed with Opti-MEM (GIBCO). Collagen Type I
(Millipore) was diluted to a final concentration of 1 mg/mL with
DMEM (GIBCO), and pH was adjusted with 5 N NaOH. 96-well
plates were coated with 75 mL of collagen matrix. After serum star-
vation overnight in Opti-MEM, aortic rings (0.5 to 1 mm) were
transferred to the 96-well plate, and after 1 hr, 150 mL of Opti-
MEM supplemented with 2.5% FBS (PAA), penicillin-streptomycin
(PAA), 30 ng/mL vascular endothelial growth factor (VEGF)
(Millipore), and GSOs (15 ng/mL) was added to each well. Micro-
vessel outgrowth was quantified after 5 days by live phase-contrast
microscopy (Axiovert 40C, Carl Zeiss). Starting from a specific
point on the ring, each microvessel emerging from the ring was
counted as a sprout and individual branches arising from each mi-
crovessel were counted as a separate sprout working around the
ring clockwise.
RIP
RIP was performed using the EZMagna RIP kit (Millipore), according
to the manufacturer’s instructions. 3T3 cells were grown to 90%
confluency and lysed in complete RIP lysis buffer. Cell lysates were
incubated with RIP buffer containing magnetic beads conjugated
with antibodies against MEF2A (Abcam ab86755) and rabbit control
IgG (Millipore PP64B). Before immunoprecipitation, 10% of cell
lysate was taken and served as 10% input control. Next, samples
were treated with proteinase K to digest protein, and RNA was iso-
lated using a standard TRIzol-chloroform extraction protocol.
Statistical Analysis
Results are expressed as mean ± SEM. In vitro experiments were per-
formed in triplicate and represent at least three independent experi-
ments. Differences between groups were tested using Student’s t tests.
p values of < 0.05 were considered statistically significant.
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